Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

Autor: S. Peters, J.-L. Pujol, U. Dafni, M. Dómine, S. Popat, M. Reck, J. Andrade, A. Becker, D. Moro-Sibilot, A. Curioni-Fontecedro, O. Molinier, K. Nackaerts, A. Insa Mollá, R. Gervais, G. López Vivanco, J. Madelaine, J. Mazieres, M. Faehling, F. Griesinger, M. Majem, J.L. González Larriba, M. Provencio Pulla, K. Vervita, H. Roschitzki-Voser, B. Ruepp, P. Mitchell, R.A. Stahel, C. Le Pechoux, D. De Ruysscher, R. Stahel, A. Hiltbrunner, M. Pardo-Contreras, A. Gasca-Ruchti, N. Giacomelli, R. Kammler, N. Marti, R. Pfister, A.C. Piguet, S. Roux, S. Troesch, M. Schneider, R. Schweri, I. Zigomo, Z. Tsourti, P. Zygoura, S. Tsouprou, M. Kassapian, G. Dimopoulou, C. Andriakopoulou, F. Morin, E. Amour, G. Mariaule, N. Archirel, M. Fernandez, E. Pereira, L. Benito, K. Lopez, A. Hernández, S. Chinchen, H. Jurkovic, A. Livingstone, J. Mitchell, M. Walker, S. Ng, C. Steer, K. Briscoe, A. Saqib, E. Abdi, B. Houghton, K. O’Byrne, B.R. Chittajallu, B.G. Hughes, A. Black, H. Werner, G. Zalcman, F. Vaylet, P. Merle, I. Monnet, N. Girard, P.-J. Souquet, F. Barlesi, D. Debieuvre, H. Senellart, M. Poudenx, A. Dixmier, D. Pouessel, J. Cadranel, H. Lena, E. Quoix, S. Friard, C. Audigier-Valette, E. Pichon, K. Kokowski, H. Kirchen, A. Tufman, C. De-Colle, J. de Langen, A. Insa, B. Massutí, M.P. Pulla, S.P. Aix, N. Villanueva, G.L. Vivanco, K. Franks, R. Califano

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
ETOP/IFCT 4-12 STIMULI Collaborators 2022, ' Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial ', Annals of Oncology, vol. 33, no. 1, pp. 67-79 . https://doi.org/10.1016/j.annonc.2021.09.011
Annals of Oncology, 33(1), 67-79. Oxford University Press

BACKGROUND: Concurrent chemotherapy and thoracic radiotherapy followed by prophylactic cranial irradiation (PCI) is the standard treatment in limited-disease small-cell lung cancer (LD-SCLC), with 5-year overall survival (OS) of only 25% to 33%. PATI

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19c0cd2636f83c5b87a3871c7a3d45ee
https://lirias.kuleuven.be/handle/123456789/682788

Inhibiteurs du check-point immunitaire en néo-adjuvant dans les cancers bronchiques non à petites cellules localisés : essai IoNESCO

Autor: Xavier Mignard, Bertrand Mennecier, Marie Wislez, Radj Gervais, Martine Antoine, Gérard Zalcman, Bernard Milleron, Denis Moro-Sibilot, Franck Morin, E. Amour, Charles Dayen

Publikováno v: Revue des Maladies Respiratoires. 35:983-988

Resume Etat des connaissances Programmed cell death-ligand 1 (PD-L1) est une proteine membranaire facilitant l’echappement tumoral vis-a-vis de l’immunite. Le durvalumab est un anticorps monoclonal bloquant l’interaction PD-L1/PD-1 entre lympho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e873bcf49b3034922c6afd239d452cec
https://doi.org/10.1016/j.rmr.2018.08.006

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

Autor: Julien Mazieres, Pascal Do, Gérard Zalcman, O. Bylicki, Jacques Cadranel, Sylvie Lantuejoul, Franck Morin, Florian Guisier, Laurent Greillier, David Planchard, Olivier Molinier, Clarisse Audigier-Valette, Didier Debieuvre, Catherine Ligeza-poisson, M. Locatelli-Sanchez, Romain Corre, Delphine Carmier, Thierry Urban, Isabelle Monnet, Denis Moro-Sibilot, E. Amour, Arnaud Scherpereel, Sandrine Hiret, Séverine Fraboulet-Moreau

Publikováno v: The Lancet Oncology
The Lancet Oncology, 2019, 20 (2), pp.239-253. ⟨10.1016/S1470-2045(18)30765-4⟩

There is no recommended therapy for malignant pleural mesothelioma that has progressed after first-line pemetrexed and platinum-based chemotherapy. Disease control has been less than 30% in all previous studies of second-line drugs. Preliminary resul

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae99b54465162f6dcacf656787abcc08
https://hal.archives-ouvertes.fr/hal-02570690

Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial

Autor: Julien Mazieres, Denis Moro-Sibilot, Pascal Do, David Planchard, Catherine Ligeza-poisson, Luc Thiberville, O. Bylicki, E. Amour, Clarisse Audigier-Valette, Arnaud Scherpereel, Franck Morin, Romain Corre, Olivier Molinier, Thierry Urban, M. Locatelli-Sanchez, Gérard Zalcman, Laurent Greillier, Isabelle Monnet

Publikováno v: Journal of Clinical Oncology
Journal of Clinical Oncology, American Society of Clinical Oncology, 2017

LBA8507 Background: To date, no treatment is recommended in MPM pts progressing after 1st-line pemetrexed-platinum doublet. Disease control rate (DCR) is nd-line setting. Preliminary results suggested possible activity of anti-PD-1 mAb in 2nd/3rd-lin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f85faca7f515b429caf0136a70d8a4b1
https://hal.archives-ouvertes.fr/hal-01676507

Second/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD)

Autor: Olivier Molinier, J. Mazieres, Thierry Urban, D. Moro-Sibilot, Sylvie Lantuejoul, G. Zalcman, Franck Morin, C. Ligeza-Poisson, Solenn Brosseau, Isabelle Monnet, M. Locatelli-Sanchez, Arnaud Scherpereel, Laurent Greillier, Romain Corre, Florian Guisier, O. Bylicki, David Planchard, P. Do, E. Amour, Clarisse Audigier-Valette

Publikováno v: Annals of Oncology. 30:v747

Background The phase IIR trial IFCT-1501 (MAPS2) tested nivo or nivo+ipi in pts with relapsed MPM as second/third-line. This trial reached its primary endpoint with 40% or more of pts with disease control in both arms. We now focus on long-term survi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8f7908ba7f707ca79048ed18597f83a3
https://doi.org/10.1093/annonc/mdz266